Form 4: Prothena Corp Public Ltd Co: Officer Acquires Stock Options

Chad J. Swanson, Chief Development Officer of Prothena Corp Public Ltd Co, reports the acquisition of stock options.

Summary

• Chad J. Swanson, Chief Development Officer of Prothena Corp Public Ltd Co, filed a Form 4 on October 3, 2024.
• The report details the acquisition of 40,000 stock options on October 1, 2024, at an exercise price of $16.65.
• These options vest over four years, starting October 1, 2025, with 25% vesting initially and the remainder vesting monthly thereafter, contingent upon continued employment.
• The options expire on October 1, 2034.

Sentiment

Score: 7

Explanation: The document reflects a standard executive compensation practice, suggesting stability and alignment of interests. It's a neutral to slightly positive indicator.

Positives

• The acquisition of stock options by a key officer can be seen as a positive sign, aligning the officer's interests with those of the shareholders.

Future Outlook

The vesting schedule indicates a long-term commitment from the officer to the company's success.

Industry Context

Stock option grants are a common form of executive compensation in the biotechnology industry, aligning management's interests with shareholder value.

Comparison to Industry Standards

• Stock option grants are a typical component of executive compensation packages in the biotech industry.
• Companies like Amgen, Biogen, and Gilead Sciences also utilize stock options to incentivize their executives.
• The vesting schedule and exercise price are generally in line with industry norms for similar-sized companies.

Stakeholder Impact

• Shareholders may view the stock option grant as a positive incentive for the Chief Development Officer to drive company growth.
• Employees may see this as a sign of the company's commitment to its leadership team.

Key Dates